PH12020500098A1 - Improved dual specific polypeptide molecule - Google Patents

Improved dual specific polypeptide molecule

Info

Publication number
PH12020500098A1
PH12020500098A1 PH12020500098A PH12020500098A PH12020500098A1 PH 12020500098 A1 PH12020500098 A1 PH 12020500098A1 PH 12020500098 A PH12020500098 A PH 12020500098A PH 12020500098 A PH12020500098 A PH 12020500098A PH 12020500098 A1 PH12020500098 A1 PH 12020500098A1
Authority
PH
Philippines
Prior art keywords
polypeptide molecule
specific polypeptide
dual specific
improved dual
region derived
Prior art date
Application number
PH12020500098A
Other languages
English (en)
Inventor
Martin Hofmann
Felix Unverdorben
Sebastian Bunk
Dominik Maurer
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017115966.5A external-priority patent/DE102017115966A1/de
Priority claimed from PCT/EP2018/069151 external-priority patent/WO2019012138A1/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PH12020500098A1 publication Critical patent/PH12020500098A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12020500098A 2017-07-14 2020-01-14 Improved dual specific polypeptide molecule PH12020500098A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762532713P 2017-07-14 2017-07-14
DE102017115966.5A DE102017115966A1 (de) 2017-07-14 2017-07-14 Polypeptidmolekül mit verbesserter zweifacher Spezifität
DE102017119866 2017-08-30
US201862658318P 2018-04-16 2018-04-16
DE102018108995 2018-04-16
PCT/EP2018/069151 WO2019012138A1 (en) 2017-07-14 2018-07-13 POLYPEPTIDE MOLECULE WITH IMPROVED DOUBLE-SPECIFICITY

Publications (1)

Publication Number Publication Date
PH12020500098A1 true PH12020500098A1 (en) 2020-12-07

Family

ID=70848164

Family Applications (2)

Application Number Title Priority Date Filing Date
PH12020500098A PH12020500098A1 (en) 2017-07-14 2020-01-14 Improved dual specific polypeptide molecule
PH12020500095A PH12020500095A1 (en) 2017-07-14 2020-01-14 Improved dual specific polypeptide molecule

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH12020500095A PH12020500095A1 (en) 2017-07-14 2020-01-14 Improved dual specific polypeptide molecule

Country Status (6)

Country Link
JP (1) JP2021019626A (enrdf_load_stackoverflow)
CL (2) CL2020000097A1 (enrdf_load_stackoverflow)
HR (1) HRP20210759T1 (enrdf_load_stackoverflow)
IL (2) IL272045B1 (enrdf_load_stackoverflow)
PH (2) PH12020500098A1 (enrdf_load_stackoverflow)
ZA (1) ZA202000636B (enrdf_load_stackoverflow)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383596B (es) * 2013-03-14 2025-03-14 Macrogenics Inc Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.

Also Published As

Publication number Publication date
CL2020000097A1 (es) 2020-05-29
CL2020000098A1 (es) 2020-05-29
IL272045B1 (en) 2025-06-01
HRP20210759T1 (hr) 2021-06-11
PH12020500095A1 (en) 2020-12-07
ZA202000636B (en) 2021-07-28
IL272046A (en) 2020-03-31
JP2021019626A (ja) 2021-02-18
IL272045A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
MX2020011744A (es) Molecula de polipeptido con especificidad dual mejorada.
WO2017147383A8 (en) Modified cells for immunotherapy
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
NZ778787A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
EP4039710A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
AU2018338418A1 (en) Anti-HLA-A2 antibodies and methods of using the same
WO2016199140A8 (en) T cell receptor like antibodies having fine specificity
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
MX384246B (es) POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.
EP4273233A3 (en) Mr1 restricted t cell receptors for cancer immunotherapy
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
HK1258218A1 (zh) T細胞受體(tcr)結合抗體及其應用
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
PH12020500098A1 (en) Improved dual specific polypeptide molecule
TH2001000190A (th) โมเลกุลโพลีเปปไทด์ความจำเพาะคู่ที่ปรับปรุง
EA202090250A1 (ru) Усовершенствованная молекула полипептида с двойной специфичностью
WO2021016534A3 (en) Antigenic polypeptides and methods of use thereof
AR121984A2 (es) Métodos de preparación de células que expresan receptores de antígenos quiméricos
MA49561A (fr) Molécule polypeptidique améliorée à double spécificité
NZ784454A (en) Antigen binding proteins that bind pd-l1